IMMUTRAIN is an Innovative Training Network which received 3,6 Mio. € from the EU Marie Curie Actions for four years (2015-2019). It brings together experts in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids with a considerable industrial involvement. The network comprises nine academic research groups and five industrial partners in a total of nine European countries. IMMUTRAIN creates actively synergies between those sectors by forming and promoting young researchers to match the challenges of immunotherapies. Particular focus is placed on combinatorial therapies and on the new emerging field of bispecific antibodies used to target both the tumor and the patient´s immune system. 15 Ph. D. students (Early Stage Researchers, ESR) reinforced by the project leaders investigate innovative therapeutic strategies and provide the rationale for future clinical trials. Throughout their projects, ESR learn to integrate academic and industrial aspects and sharpen their experimental and complementary skills in a well-designed and diversified training program. This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement N° 641549.